Subject index of volume 25

Aclacinomycin 135
Acute lymphoblastic leukemia 65
Acute myelogenous leukemia 223
Adryamicin 131, 177
Advanced cancer 299
Alkylating activity 257
Alkylating agents 32, 103, 161
Alkylation 257
Alopecia 306
Anthracyclines 252
Antiemetic 291
Antiemetics 449
Antiestrogen 247
Anti-tumor activity 205, 345
Antitumor effects 99
Ara-AC 117
1-β-D-Arabinofuranosyl-5-azacytosine 19
Ara-C 252
Ara-C leukemia 51
Aromatase inhibitor 95
Athymic mice 117
5-aza-2′-Deoxycytidine 51

BCNU 32, 227
Bladder cancer 267
B16 melanoma 221
BMY-28090 195
Bone marrow cells 295
Bone marrow transplantation 55, 210, 213
Brain 311, 320
Brain metastases 382
Breast cancer 73, 286
–, advanced 247, 459, 463
–, metastatic 435
Brequinar sodium 345
BRL 43694 377
Bromodeoxyuridine 45
Bronchal carcinoma 139
Buserelin 219
Busulfan kinetics 55

Candida albicans 75
Carbogen breathing 99
Carboplatin 202, 367, 382, 395
Cardioprotection 326
Cardiotoxicity 333
CDDP 32
Cell differentiation 189
Cellular metabolism 19
Cellular pharmacology 177
Cerebral metastases 263
Chemosensitivity 337
Chemotherapeutic agents 342
Chemotherapy 65, 454
–, intravesical 267
Childhood 65
Children 143
Chiral HPLC 440
Chlorambucil 320
Chlorambucil esters 311
Chlorambucil-tertiary butyl ester 320
Chloroethylnitrosoureas 149
Cholestasis 227

Cisplatin 89, 114, 131, 380, 389, 395, 405, 411
–, high-dose 62, 291, 355, 373
Cisplatin accumulation 236
Cisplatin 5-HT_3 antagonist 377
Cisplatin nephrotoxicity 1, 156
Cisplatin resistance 236
Colon carcinoma cells 430
Colonic carcinoma cells 37
Combination chemotherapy 135, 161
Compartmentalization 295
Continuous-infusion 361
Copper(II)-doxorubicin chelate 333
Cross-resistance 425
Cy 233 205
Cyclophosphamide 89, 99, 213, 355, 367
Cytokines 342
Cytosine arabinoside 418, 454
Cytotoxicity 37, 77, 84, 124, 286, 418

Daunorubicin 252
3-Deazauridine 51
4-Demethoxydaunorubicin 445
Dichloroetretinate 279
5,10-Dideaza-5,6,7,8-tetrahydrofolic acid 173
Dipyridamole 124, 167
Disseminated malignant melanoma 263
DMBA-induced mammary tumor 95
DNA 19
DNA damage 77, 430
DNA incorporation 45
DNA synthesis 418
Down's syndrome 384
Doxifluridine 274
Doxorubicin 77, 89, 252, 286, 295, 326, 430, 435, 459
Drug accumulation 77
Drug distribition 139
Drug resistance 241

Elsamicin A 195
Epithelial ovarian cancer 355
Etoposide 210, 361, 367
Experimental chemotherapy 205

FCE 24304 95
Fischer 344 rat 109
Flow cytometry 45, 149
Fluorodeoxyuridine 124
5-Fluorouracil 37, 131
Fluosol-DA 99
d,l-Folinic acid 440
Fotemustine 263, 337
Fructose-1,6-diphosphate 326

Glutathione protection 355
GR38032F 291
Gynecological cancer cells 89

4-HC 32
Hepatic cytochrome P-450 227, 342
Hepatotoxicity 65
Herpes viruses 75
High-dose cisplatin 62
HL-60 cells 189

Hodgkin's disease 387
HPLC analysis 195
Human lymphoid cells 19
Human tumors 117
Hydroxyurea 223
Hyperthermia 342

Idarubicin 304
Ifosfamide 70, 139, 306, 380
[^{131}I]-Metaidobenzylguanidine 143
Imidazotetrazines mitozolomide 149
Infusion 274
–, intraperitoneal 454
Inhibition 25
Interferon gamma 308
Iproplatin 10, 395

Ketone tests 371
Kidney 389

L1210 51
L1210 cells 15, 411
Leukemia cells 241
Leukemic cells 252
Lipid peroxidation 210
Liver metastases 73
Lonidamine 32
L-Phenylalanine mustard 32
L1210 tumors 173
Lysozyme 221

Macrophages 308
Mastectomy 286
Melphalan, high-dose 449
Merbarone 109
Mesna 70
Metabolism 10, 15
Metastases 221
Metastasis 425
Metastatic melanoma 373
Methallothionein 411
Methotrexate 65, 187, 173, 384
Methyltetrahydrofolic acid 440
Mitomycin 380
Mitoxantrone 73
Mitozolomide 352
Monoclonal antibody 405
3-Month depot 219
Morphological change 114
Mouth ulcers 75
Myeloma 449

N-Benzyladriamycin-14-valerate 177
Nephrotoxicity 109
Neuroblastoma 25, 143
Neuroblastoma cells 114
Neuropathy 62
Neuropenic patients 75
Nitrosourea 337
Non-small-cell lung cancer 380
NSC 361456 425

O_6-Alkylguanine 103
O_6-Methylguanine 103
Ondansetron 449
Ovarian cancer 257, 304, 382
–, epithelial 355
Ovarian carcinoma cells 236
Oxaliplatin 299
Oxazaphosphorines 306

Pancreatic cancer 131
P-Glycoprotein 241
Pharmacodynamics 361
Pharmacokinetics 55, 139, 247, 257, 274, 279, 311, 320, 352, 382, 435, 440, 445
Pharmacology 167, 405, 418
Phyllanthoside metabolite 184
Picamycin 223
Plasma 195, 311
Plasminogen activator 25
Platinum distribution 389
Prednimustine 311
Prochlorperazine 156
Prophylaxis 306
Prostatic cancer 219
Pteridines 308
Purine analogs 189
Pyrazine 425

Radiation 131
Rats 95
Refractory non-Hodgkin's lymphoma 135
Resistance 411
Retinoic acid 25
RNA processing 37
RO11-2933 77

Small-cell lung cancer 202, 213, 367
Solid malignancies 345
Spectrofluorimetry 149
Sulfonyl urea 84
Synergy 173

Temozolomide 149
Teniposide 463
Thiols 306
Thio-TEPA 257
Thio-TEPA pharmacokinetics 267
Tiapamil analog 77
Tissue distribution 286
Toremifene 247
Toxicity 184, 299, 352, 459
Toxicology 395
Tubular nephrotoxicity 70
Tween 80 267

Uptake 15
Urinary mesna 371
Urine 195

Vepesid 387
Vincristine 202, 367

Xenografts 84, 103, 117